Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Convergent action on AMR identified as an important area of intervention
Urges Innovators to produce quality products that can be deployed at scale
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
